Sanara MedTech annual gross margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanara MedTech's gross margin was 92.71% for fiscal 2025.
View full Sanara MedTech company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 92.71% | +2.10 pp |
| 2024 | 2024-12-31 | 90.61% | +2.69 pp |
| 2023 | 2023-12-31 | 87.92% | +1.79 pp |
| 2022 | 2022-12-31 | 86.12% | −4.30 pp |
| 2021 | 2021-12-31 | 90.43% | +0.80 pp |
| 2020 | 2020-12-31 | 89.63% | −0.09 pp |
| 2019 | 2019-12-31 | 89.72% | −1.59 pp |
| 2018 | 2018-12-31 | 91.31% | +4.09 pp |
| 2017 | 2017-12-31 | 87.22% | +4.35 pp |
| 2016 | 2016-12-31 | 82.87% | +9.32 pp |
| 2015 | 2015-12-31 | 73.55% | +4.07 pp |
| 2014 | 2014-12-31 | 69.47% | +15.40 pp |
| 2013 | 2013-12-31 | 54.08% | +22.12 pp |
| 2012 | 2012-12-31 | 31.96% | −31.86 pp |
| 2011 | 2011-12-31 | 63.81% | +22.94 pp |
| 2010 | 2010-12-31 | 40.88% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 92.96% | +0.47 pp |
| Q1 2026 | 2026-03-31 | 93.08% | +0.91 pp |
| Q4 2025 | 2025-12-31 | 93.19% | +1.75 pp |
| Q3 2025 | 2025-09-30 | 92.88% | +2.07 pp |
| Q2 2025 | 2025-06-30 | 92.49% | +2.46 pp |
| Q1 2025 | 2025-03-31 | 92.17% | +2.37 pp |
| Q4 2024 | 2024-12-31 | 91.45% | +1.56 pp |
| Q3 2024 | 2024-09-30 | 90.81% | +1.74 pp |
| Q2 2024 | 2024-06-30 | 90.04% | +3.92 pp |
| Q1 2024 | 2024-03-31 | 89.80% | +3.50 pp |
| Q4 2023 | 2023-12-31 | 89.89% | +5.36 pp |
| Q3 2023 | 2023-09-30 | 89.07% | +6.16 pp |
| Q2 2023 | 2023-06-30 | 86.11% | −3.98 pp |
| Q1 2023 | 2023-03-31 | 86.31% | −3.39 pp |
| Q4 2022 | 2022-12-31 | 84.53% | −4.34 pp |
| Q3 2022 | 2022-09-30 | 82.92% | −8.20 pp |
| Q2 2022 | 2022-06-30 | 90.09% | −1.36 pp |
| Q1 2022 | 2022-03-31 | 89.69% | −0.84 pp |
| Q4 2021 | 2021-12-31 | 88.87% | −147.10 pp |
| Q3 2021 | 2021-09-30 | 91.11% | +1.51 pp |
| Q2 2021 | 2021-06-30 | 91.45% | +3.21 pp |
| Q1 2021 | 2021-03-31 | 90.53% | +41.32 pp |
| Q4 2020 | 2020-12-31 | 235.97% | +144.92 pp |
| Q3 2020 | 2020-09-30 | 89.60% | −0.60 pp |
| Q2 2020 | 2020-06-30 | 88.25% | −0.65 pp |
| Q1 2020 | 2020-03-31 | 49.20% | −39.16 pp |
| Q4 2019 | 2019-12-31 | 91.05% | +38.63 pp |
| Q3 2019 | 2019-09-30 | 90.20% | −2.40 pp |
| Q2 2019 | 2019-06-30 | 88.90% | −4.11 pp |
| Q1 2019 | 2019-03-31 | 88.37% | −0.88 pp |
| Q4 2018 | 2018-12-31 | 52.42% | −33.56 pp |
| Q3 2018 | 2018-09-30 | 92.60% | +7.45 pp |
| Q2 2018 | 2018-06-30 | 93.02% | +4.33 pp |
| Q1 2018 | 2018-03-31 | 89.25% | +0.07 pp |
| Q4 2017 | 2017-12-31 | 85.98% | +4.95 pp |
| Q3 2017 | 2017-09-30 | 85.15% | +0.16 pp |
| Q2 2017 | 2017-06-30 | 88.69% | +5.40 pp |
| Q1 2017 | 2017-03-31 | 89.18% | +6.59 pp |
| Q4 2016 | 2016-12-31 | 81.03% | +19.54 pp |
| Q3 2016 | 2016-09-30 | 84.99% | +6.75 pp |
| Q2 2016 | 2016-06-30 | 83.29% | +10.85 pp |
| Q1 2016 | 2016-03-31 | 82.59% | +4.00 pp |
| Q4 2015 | 2015-12-31 | 61.49% | −20.58 pp |
| Q3 2015 | 2015-09-30 | 78.23% | +12.86 pp |
| Q2 2015 | 2015-06-30 | 72.44% | +21.94 pp |
| Q1 2015 | 2015-03-31 | 78.59% | +3.32 pp |
| Q4 2014 | 2014-12-31 | 82.08% | +5.66 pp |
| Q3 2014 | 2014-09-30 | 65.37% | +15.87 pp |
| Q2 2014 | 2014-06-30 | 50.50% | +5.76 pp |
| Q1 2014 | 2014-03-31 | 75.27% | +32.67 pp |
| Q4 2013 | 2013-12-31 | 76.41% | +39.50 pp |
| Q3 2013 | 2013-09-30 | 49.50% | +7.63 pp |
| Q2 2013 | 2013-06-30 | 44.74% | +16.50 pp |
| Q1 2013 | 2013-03-31 | 42.60% | +56.24 pp |
| Q4 2012 | 2012-12-31 | 36.92% | −36.02 pp |
| Q3 2012 | 2012-09-30 | 41.87% | +220.93 pp |
| Q2 2012 | 2012-06-30 | 28.24% | −34.57 pp |
| Q1 2012 | 2012-03-31 | −13.64% | −103.55 pp |
| Q4 2011 | 2011-12-31 | 72.94% | +238.62 pp |
| Q3 2011 | 2011-09-30 | −179.07% | −254.35 pp |
| Q2 2011 | 2011-06-30 | 62.82% | — |
| Q1 2011 | 2011-03-31 | 89.91% | — |
| Q3 2010 | 2010-09-30 | −165.68% | — |
| Q2 2010 | 2010-06-30 | 75.28% | — |
Over the last five reported fiscal years, Sanara MedTech's gross margin increased from 89.63% to 92.71%, a change of +3.08 percentage points. The latest reported quarter, Q2 2026, shows 92.96%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanara MedTech filings at SEC.gov ↗